Reviva Pharmaceuticals Receives European Patent for Brilaroxazine

Reviva Pharmaceuticals Receives European Patent for Brilaroxazine in Treating Pulmonary Hypertension

Overview

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) announced today that it has been granted European Patent EP3244896 by the European Patent Office (EPO) for the use of brilaroxazine in treating pulmonary hypertension (PH). This patent adds to Reviva's existing global patent protection in key markets, including the United States, China, and Japan. Brilaroxazine, which has also received Orphan Drug Designation from the FDA for pulmonary arterial hypertension (PAH), demonstrates potential in treating PH across various patient groups, including those with COPD or sickle cell disease (SCD).

Enhanced Therapeutic Potential

• Reviva, highlighted that this new patent enhances brilaroxazine's therapeutic potential for inflammatory conditions linked to disruptions in serotonin signaling, such as PH. 
• Brilaroxazine has shown positive clinical safety and tolerability profiles in extensive trials involving over 800 subjects. 
• Recent Phase 3 studies in schizophrenia demonstrated significant reductions in proinflammatory biomarkers, supporting its anti-inflammatory and antifibrotic activities observed in animal models of PAH.

About Brilaroxazine

• Brilaroxazine, a novel compound discovered in-house by Reviva, targets serotonin and dopamine receptors implicated in conditions like schizophrenia, psoriasis, and interstitial lung diseases such as PAH and idiopathic pulmonary fibrosis (IPF). 
• Its successful Phase 3 RECOVER-1 trial in schizophrenia achieved all primary and secondary endpoints, with notable reductions in major symptom domains and cytokine levels compared to placebo. 
• Further clinical development is planned for indications like bipolar disorder, major depressive disorder (MDD), and attention-deficit/hyperactivity disorder (ADHD).

About Reviva Pharmaceuticals

Reviva's comprehensive development strategy includes regulatory compliant toxicology and safety studies, reinforcing brilaroxazine's potential across neuropsychiatric and inflammatory disease indications.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!